All In Biotech

Drug Trial Radar · NCT02927314

A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

Last checked: Nov 19, 2026Latest source record: Mar 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Nov 27, 2017

Primary completion

Mar 1, 2020

Study completion Mar 1, 2020

Sponsor

Lead sponsor
Can-Fite BioPharmaIndustry
Sponsor type
Industry
First posted
Oct 7, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with NAFLD and NASH.

Conditions

  • Non-alcoholic Steatohepatitis (NASH)

Interventions

  • CF102Drug

    orally q12h

  • PlaceboDrug

    orally q12h

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of CF102 as determined by change in serum alanine aminotransferase (ALT) levelsTime frame: 12 weeks
  2. Efficacy of CF102 as determined by change in magnetic resonance imaging-determined hepatic steatosisTime frame: 12 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Can-Fite Investigational Site #318

    Jerusalem, Israel

  • Can-Fite Investigational Site #319

    Nazareth, Israel

  • Can-Fite Investigational Site #311

    Petah Tikva, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.